

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 22 NOVEMBER 2024

The Board of Directors (the “**Board**”) of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the “**Company**”) wishes to announce that at the Extraordinary General Meeting (“**EGM**”) of the Company held on 22 November 2024, all resolutions relating to the matters set out in the Notice of EGM dated 7 November 2024 (superseding the Notice of EGM dated 27 September 2024) were passed.

The results of the poll on each of the resolutions put to vote at the EGM are set out below. All the resolutions were duly passed at the EGM.

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
1	To consider and approve the proposed disposal of 13% equity interest in the registered capital of Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司) to Hialeon China Co., Ltd., and the entry into an equity transfer agreement in relation thereto as an interested person transaction	65428508	64997426	99.341	354582	0.542	76500	0.117
2	To consider and approve the	391284036	390907334	99.904	301802	0.077	74900	0.019

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	proposed entry into the amended and restated equity joint venture contract with respect to Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司) between Haleon UK Services Limited, Haleon China Co., Ltd. and the Company, and the proposed execution of the amended and restated articles of association of Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司)							

Details of parties who are required to abstain from voting on any resolution(s)

Pursuant to Rule 919 of the Listing Manual, Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) ("TPH") (being the controlling shareholder of the Company) which holds 325,855,528 A-shares in the Company, and Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd. (being a wholly-owned subsidiary of TPH) which holds 5,265,000 S-shares in the Company, had abstained from voting on resolution 1. Further, Jinhushen Biological Medical Science and Technology Co., Ltd (津沪深生物医药科技有限公司) (being the controlling shareholder of TPH) which holds 4,497 A-shares in the Company, had also abstained from voting on resolution 1. In addition, TPH and its associates did not accept nominations as proxies or otherwise for voting on resolution 1 at the EGM, unless they were given specific instructions by independent shareholder(s) as to how to vote.

Scrutineer

Pursuant to Rule 704(16) of the Listing Manual, Drewcorp Services Pte Ltd acted as the Company's scrutineer for the EGM.

BY ORDER OF THE BOARD

Jiao Yan
Secretary to the Board of Directors
22 November 2024